Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Nature Medicine  (IF53.44),  Pub Date : 2021-12-01, DOI: 10.1038/s41591-021-01590-5
Steven G. Deeks, Nancie Archin, Paula Cannon, Simon Collins, R. Brad Jones, Marein A. W. P. de Jong, Olivier Lambotte, Rosanne Lamplough, Thumbi Ndung’u, Jeremy Sugarman, Caroline T. Tiemessen, Linos Vandekerckhove, Sharon R. Lewin

Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years.